作者: H. Murakami , T. Tamura , T. Takahashi , H. Nokihara , T. Naito
DOI: 10.1007/S00280-011-1738-1
关键词:
摘要: Purpose This Phase I study determined the maximum-tolerated dose (MTD) of afatinib (Afatinib is an investigational compound and its safety efficacy have not yet been established) (BIBW 2992; trade name approved by FDA), irreversible inhibitor epidermal growth factor receptor (EGFR)/human (HER)1 2, up to a 50 mg/day in advanced non-small cell lung cancer (NSCLC), establish recommended for II.